As of December 31, 2024, AnaptysBio had cash, cash equivalents, and investments greater than $420 million and anticipates ...

AnaptysBio shares rose 7.2% on a share-repurchase program authorized to buy back up to $75 million of the company's common stock. Shares were recently trading around $18.31. The stock is down 15% over ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its ...

Shares of AnaptysBio (NASDAQ: ANAB) climbed 12% today as the company announced a significant stock repurchase plan, signaling confidence in its financial position and future prospects. The ...

Intuitive Machines reported fourth-quarter revenue of $54.66 million, missing analyst estimates of $55.77 million, according ...

Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or ...